Revlimid Dose 25 mg in Association With (R-CHOP) in the Treatment Follicular Lymphoma
The purpose of the study is to assess the efficacy of the association of Lenalidomide (Revlimid) and R-CHOP (Rituximab, Cyclophosphamide, Doxorubicin, vincristine and Prednisone) in a population of patients with follicular lymphoma as measured by the response rate at the end of treatment.
Follicular Lymphoma
DRUG: Lenalidomide and R-CHOP
Complete Response Rate (CR+CRu), at the end of complete treatment, average of 24 weeks
Overall survival, from the date of inclusion, average of 6 years|Duration of response, from the date of first documentation of a response, average of 24 weeks
The purpose of the study is to assess the efficacy of the association of Lenalidomide (Revlimid) and R-CHOP (Rituximab, Cyclophosphamide, Doxorubicin, vincristine and Prednisone) in a population of patients with follicular lymphoma as measured by the response rate at the end of treatment.